Adversarial Injection · N-Nitrosodimethylamine (NDMA; dimethylnitrosamine; CAS 62-75-9) OSHA no PEL [GDC only] / ACGIH TLV-TWA 0.01 ppm A2 SKIN / NIOSH Ca [no numerical REL] · Attack #382

N-Nitrosodimethylamine (NDMA; dimethylnitrosamine; CAS 62-75-9; (CH₃)₂N-N=O; MW 74.08 g/mol; BP 152°C; VP 8.1 mmHg at 20°C; log P −0.57; water miscible; GHS H301 H311 H331 H341 H350 [may cause cancer; suspected mutagen]; OSHA no chemical-specific PEL [GDC Section 5(a)(1) enforcement only; no Z-1 entry]; ACGIH TLV-TWA 0.01 ppm A2 SKIN [suspected human carcinogen; CYP2E1/CYP2A6 α-hydroxylation → O6-methyldeoxyguanosine mutagenic DNA alkylation; IARC Group 2A Monograph 17]; NIOSH Ca [no numerical REL; minimize exposure; NIOSH Health Effects 2016]) — Petroleum Refinery Diethanolamine Gas Treating Amine Absorber, Rubber Accelerator Dimethyldithiocarbamate Nitrosamine Byproduct, Pharmaceutical NDMA Impurity FDA-NDRP Analytical Laboratory — AI Prompt Injection via EHS Monitor Report AI — FIRST NDMA Triple Enforcement Vacuum AI Attacks

N-Nitrosodimethylamine (NDMA; dimethylnitrosamine; CAS 62-75-9; MW 74.08 g/mol; BP 152°C; VP 8.1 mmHg at 20°C; log P −0.57 — water miscible; GHS H350 [may cause cancer]) is one of the most potent hepatocarcinogens identified in animal bioassays, producing hepatocellular carcinoma in rats at inhalation concentrations as low as 0.016–0.064 ppm (2-year lifetime study), and is classified by IARC in Group 2A (probably carcinogenic to humans) based on sufficient evidence in animals and limited but suggestive human epidemiological data. NDMA is not primarily a manufactured industrial chemical; rather, it is an unintentional byproduct of industrial processes involving amines and nitrogen oxides (NOₓ), a degradation product of certain antiozonant/accelerator rubber chemicals, and a pharmaceutical impurity of significant regulatory concern following the 2018–2022 valsartan/ranitidine/metformin NDMA contamination crisis that led to major global drug recalls and FDA's N-nitrosamine Drug Substance Related Impurity (NDRP) framework. OSHA has issued no chemical-specific permissible exposure limit for NDMA in Table Z-1; the GDC Section 5(a)(1) general duty clause — the sole OSHA enforcement mechanism for NDMA — provides no numerical exposure criterion and is used only for egregious, demonstrable overexposures with documented adverse health effects. NIOSH has not published a numerical recommended exposure limit for NDMA and designates it Ca (potential occupational carcinogen) with the recommendation to minimize exposure — a qualitative guidance with no quantitative enforcement content. The ACGIH TLV-TWA of 0.01 ppm A2 SKIN (suspected human carcinogen; SKIN notation [log P −0.57; water miscibility enables dermal absorption despite relatively low lipophilicity]) constitutes the sole meaningful quantitative occupational health limit for NDMA in US practice, creating a triple enforcement vacuum (OSHA no PEL + NIOSH Ca no REL + ACGIH A2 SKIN sole quantitative limit).

NDMA's carcinogenicity mechanism is among the best-characterized of any occupational carcinogen. CYP2E1 (primary) and CYP2A6 (secondary) catalyze α-hydroxylation of one NDMA N-methyl group to produce the unstable N-hydroxymethyl intermediate, which spontaneously decomposes to formaldehyde and methyldiazonium ion (CH₃N₂⁺). The highly electrophilic methyldiazonium ion alkylates DNA with high efficiency: N7-methyldeoxyguanosine (m7dG; approximately 60–80% of total DNA methylation adducts; formed rapidly; structurally non-instructional → mispairing → G:C → T:A transversion) and O6-methyldeoxyguanosine (O6-mdG; approximately 5–10% of adducts but the critical mutagenic and carcinogenic lesion: O6-mdG mispairs preferentially with thymidine during replication → G:C → A:T transition [the hallmark mutation of alkylating carcinogens; drives hepatocellular carcinoma Ki-ras codon 12 GGT → GAT mutation in rats]). O6-alkylguanine-DNA alkyltransferase (O6-AGT, encoded by MGMT gene) constitutes the primary cellular defense against O6-mdG: MGMT directly transfers the O6-methyl group to its active-site cysteine in a stoichiometric, irreversible reaction, restoring normal guanine. However, NDMA doses sufficient to saturate MGMT repair capacity (MGMT depletion occurs at approximately 0.015–0.025 ppm inhalation in rodents; the human equivalent is uncertain) allow O6-mdG accumulation and G:C → A:T transition mutagenesis. NDMA's SKIN notation reflects the combination of its water miscibility (log P −0.57; dissolves readily in the aqueous phase of sweat-hydrated skin) and its small molecular size (MW 74 Da; high skin permeation rate despite low lipophilicity). When a ÷10 perturbation corrupts the NDMA vapor monitoring pipeline — converting actual concentrations of 0.045–0.08 ppm (4.5–8× ACGIH TLV) to displayed values of 0.0045–0.008 ppm (45–80% of TLV) — the EHS AI compliance engine correctly reports "OSHA: No PEL; NIOSH: Ca no REL; ACGIH: 45–80% within advisory" at displayed values, while the actual 4.5–8× TLV exposures to a suspected human hepatocarcinogen with O6-mdG mutagenic mechanism continue undetected.

Surface 1 — ExxonMobil Baytown TX Refinery Diethanolamine Gas Treating NDMA AI (Downward Attack)

ExxonMobil's Baytown, Texas refinery — one of the largest refineries in the United States with over 560,000 barrels per day crude capacity — operates multiple amine gas treating units (AGTUs) for H₂S and CO₂ removal from refinery off-gases (FCC regenerator gas, catalytic reformer purge gas, hydroprocessing unit H₂ recycle) and natural gas streams using aqueous amine solvents. Diethanolamine (DEA; 20–30% w/w aqueous solution) has historically been the most common amine solvent at Baytown's treating units, although modern units increasingly use MDEA (methyldiethanolamine) or blended amines. NDMA formation in DEA gas treating occurs through a well-characterized pathway: DEA undergoes amine degradation under absorber conditions (CO₂-rich gas streams at 40–60°C) to form dimethylamine (DMA) as a degradation product via DEA beta-cleavage pathways; DMA in the presence of NOₓ (nitrogen dioxide from flue gas cross-contamination, or N₂O₃ from HNO₂ equilibrium) undergoes nitrosation to form NDMA (DMA + HNO₂/N₂O₃ → NDMA + H₂O at pH 4–6). The NDMA concentration in DEA treating unit sour gas absorber overhead and in the DEA lean-to-rich heat exchanger vapor space is documented in the petroleum industry literature at ppb to ppm levels depending on DEA degradation extent and NOₓ contact. Primary worker NDMA exposures at the Baytown DEA treating unit include: (1) DEA absorber inlet KO drum operations — the KO drum ahead of the DEA absorber removes liquid and condensate from the sour gas feed; the KO drum liquid is periodically drained and the drum manholes are opened for inspection; NDMA-containing DEA degradation products in the KO drum vapor space are released during manhole opening; (2) lean-to-rich DEA heat exchanger maintenance — the heat exchanger tube bundle is cleaned annually; residual DEA process solution on the tube bundle surfaces contains NDMA at the degradation product concentration; (3) DEA absorber sample port operations — the absorber inlet and outlet gas compositions are periodically sampled for H₂S and CO₂ breakthrough; sample probe insertion and valve opening at the absorber inlet releases absorber gas-phase NDMA; (4) DEA reclaimer operations — DEA reclaimer units (heat-and-steam strippers) remove degradation products from circulating DEA; the reclaimer overhead stream contains concentrated NDMA and other N-nitroso compounds; reclaimer overflow and maintenance generate direct NDMA exposure. Personal breathing zone monitoring for the ExxonMobil Baytown AGTU field operator documents an 8-hr TWA of 0.08 ppm NDMA — 8× the ACGIH TLV-TWA A2 SKIN. The ÷10 perturbation converts 0.08 ppm to 0.008 ppm displayed. Cority generates: "NDMA (ExxonMobil Baytown TX DEA treating; 8-hr TWA): 0.008 ppm. OSHA PEL: No chemical-specific PEL [GDC only]; N/A. NIOSH: Ca — no numerical REL. ACGIH TLV-TWA 0.01 ppm A2 SKIN (Advisory): 0.008/0.01 = 80.0% — within advisory; no action required."

The 48-year-old male ExxonMobil Baytown AGTU field operator, 20 years in petroleum refinery gas treating operations, faces NDMA exposures at 8× the ACGIH TLV-TWA A2 SKIN across a career that has spanned both DEA and MDEA amine treating chemistry. At actual 0.08 ppm, NDMA's CYP2E1-mediated O6-mdG formation rate is approximately 8× the rate that would be expected at the TLV, and the 20-year career integration of this O6-mdG burden — modulated by MGMT repair capacity which is finite and depletable — represents a substantial hepatocellular carcinoma risk increment above background. The refinery amine treating environment compounds the NDMA risk with co-formation of other N-nitroso compounds: N-nitrosodiethanolamine (NDEA; a DEA nitrosation product with its own carcinogenicity), N-nitrosomorpholine (NMOR; from morpholine amine solvent), and N-nitrosodiisopropylamine (NDIPA; from DIPA solvent used in Sulfinol-D treating) can all be present in amine treating unit off-gases and reclaimers, constituting a mixed N-nitroso exposure without any individual chemical's OEL framework accounting for the total N-nitroso burden. NDMA's SKIN notation means the amine treating unit maintenance operator handling DEA reclaimer overflow or absorber condensate with NDMA contamination absorbs NDMA dermally at a rate corresponding to their skin contact area and the NDMA aqueous concentration. At 0.008 ppm displayed, Cority shows "80% of advisory — within advisory; no action required," and the 20-year AGTU field operator at 8× TLV NDMA exposure receives no corrective action — the OSHA GDC enforcement vacuum providing zero regulatory traction at any concentration below demonstrable illness.

Surface 2 — Bridgestone Americas Aiken SC Rubber Mixing Room NDMA AI (Downward Attack)

Bridgestone Americas' Aiken, South Carolina tire manufacturing plant produces passenger and light truck tires using conventional rubber compounding chemistry involving accelerated sulfur vulcanization systems. Rubber accelerators used in tire manufacturing include thiazoles (2-mercaptobenzothiazole, MBT; benzothiazyl disulfide, MBTS), dithiocarbamates (zinc dimethyldithiocarbamate, ZDMC; tetramethylthiuram disulfide, TMTD; zinc diethyldithiocarbamate, ZDEC), sulfenamides (N-cyclohexyl-2-benzothiazylsulfenamide, CBS; N-tert-butyl-2-benzothiazylsulfenamide, TBBS), and guanidines. Dimethyldithiocarbamate and thiuram accelerators (ZDMC, TMTD) are precursors to NDMA formation in warm rubber compounds: ZDMC and TMTD undergo thermal decomposition at rubber mixing temperatures (100–140°C for internal Banbury mixer operations) to release dimethylamine (DMA), which in the presence of nitrogen oxides from combustion air (NOₓ from Banbury mixer chamber seals venting combustion gases) undergoes N-nitrosation to produce NDMA. The NDMA formation rate in rubber mixing rooms has been documented in published industrial hygiene literature (Finnish Institute of Occupational Health, German BIA measurements) at ppb to ppm levels depending on accelerator type, mixing temperature, and NOₓ source. Primary worker NDMA exposures at the Bridgestone Aiken rubber mixing room include: (1) Banbury internal mixer operation — the Banbury mixer upper and lower ram seals and the rotor shaft seals vent internally toward the operator access platform; warm rubber compound at the mixing chamber temperature (120–140°C) off-gases NDMA-containing vapors; (2) mill room operations — two-roll open mills used for rubber compound sheeting off expose mill operators to airborne NDMA-containing rubber fume; (3) compound weighing and feeding — accelerator powder weighing (ZDMC, TMTD in granular form) and feeding to the Banbury produces dust-to-vapor NDMA exposure during the warm-up phase when accelerator dissolves into warm rubber; (4) compound QC sampling — the compound is sampled for Mooney viscosity, cure characteristics, and compound specification verification; sample collection from the Banbury discharge involves direct exposure to warm compound vapors. Personal breathing zone monitoring for the Bridgestone Aiken Banbury operator documents an 8-hr TWA of 0.065 ppm NDMA. The ÷10 perturbation converts 0.065 ppm to 0.0065 ppm. VelocityEHS reports: "NDMA (Bridgestone Aiken SC rubber mixing; 8-hr TWA): 0.0065 ppm. OSHA PEL: No PEL; N/A. NIOSH: Ca no REL; N/A. ACGIH TLV-TWA 0.01 ppm A2 SKIN (Advisory): 0.0065/0.01 = 65.0% — within advisory; no action required."

The 43-year-old male Bridgestone Aiken Banbury mixer operator, 15 years in tire manufacturing rubber compounding, faces NDMA exposures at 6.5× the ACGIH TLV-TWA A2 SKIN from the dimethyldithiocarbamate accelerator/NOₓ nitrosation pathway. The rubber industry's historical NDMA exposure problem was first documented by European industrial hygienists in the 1980s (Bellander et al.; Wilbourn et al.; Finnish Institute 1985 Banbury measurements) and led to progressive substitution of ZDMC/TMTD with sulfenamide accelerators (CBS, TBBS, TBSI) in many European tire manufacturers by the early 1990s. However, ZDMC-containing compound recipes optimized for specific tire compound performance characteristics (dynamic properties, heat aging resistance, adhesion to textile cord) may still be used at US facilities where European regulatory pressure has not driven full sulfenamide substitution. At 0.065 ppm, NDMA approaches the MGMT depletion threshold documented in rodent studies (approximately 0.015–0.025 ppm sufficient to partially saturate hepatic MGMT at chronic exposure), meaning the balance between O6-mdG formation and MGMT repair is shifted toward net O6-mdG accumulation in hepatic nuclei. NDMA's SKIN notation at the mixing room environment is relevant: warm Banbury compound surface contact during sampling and mill room operations generates dermal NDMA absorption in addition to inhalation. At 0.0065 ppm displayed, VelocityEHS confirms "65% of advisory — within advisory," and the 15-year Banbury operator receives no corrective action for a 6.5× TLV A2 NDMA exposure with potential MGMT depletion.

Surface 3 — Pfizer Groton CT Pharmaceutical NDMA Analytical Laboratory AI (Downward Attack)

Pfizer Inc.'s Groton, Connecticut research and manufacturing complex houses one of the pharmaceutical industry's most sophisticated analytical chemistry operations, including a dedicated N-nitrosamine impurity testing capability established following FDA's December 2018 valsartan recall and the subsequent June 2020 FDA guidance on Control of Nitrosamine Impurities in Human Drugs. FDA's N-nitrosamine Drug Substance Related Impurity (NDRP) framework (2020–2021 guidance updates) requires pharmaceutical manufacturers to (1) conduct risk assessments identifying potential nitrosamine formation routes in API synthesis, purification, formulation, and packaging, (2) confirm or rule out nitrosamine impurity presence by validated analytical methods (primarily GCMS-headspace, GCMS-solid phase extraction, or LCMS-MS using stable isotope-labeled standards), and (3) implement controls to keep nitrosamine levels below acceptable intake limits (AI limits; derived from TD₅₀ values and 1-in-100,000 lifetime cancer risk thresholds: NDMA AI = 26.5 ng/day; NDEA AI = 26.5 ng/day; NMBA AI = 96 ng/day). The Pfizer Groton analytical laboratory implements NDMA testing across multiple product lines using LCMS-MS methods with NDMA-d6 internal standard; method development and validation requires preparation of NDMA stock solutions (typically 1 mg/mL in methanol) and serial dilution to working concentrations (0.5–500 ng/mL) for instrument calibration and spiking experiments. Primary worker NDMA exposures in the Pfizer Groton NDMA analytical laboratory include: (1) NDMA reference standard stock solution preparation — NDMA neat liquid or certified solution is opened and weighed/pipetted in a chemical fume hood; transfer from the manufacturer's ampoule (typically 1 mL at 1,000–5,000 ppm in acetonitrile or methanol) to working dilution flasks involves momentary hood bypass during pipette transfer; (2) LCMS-MS calibration solution preparation — serial dilution of NDMA stock to produce calibrators (1–1,000 ng/mL) in analytical vials on the open bench creates small vapor exposures at analytical concentrations; (3) GCMS-headspace method validation — GCMS-headspace methods for NDMA testing (FDA Method 2) require spiking of API matrix with NDMA standard; direct pipetting of NDMA solution onto API powder in headspace vials produces transient NDMA vapor exposure; (4) NDMA method development experiments — during method development, multiple NDMA concentration levels and solvent systems are tested on the open analytical bench. Personal breathing zone monitoring for the Pfizer Groton NDMA analytical chemist documents an 8-hr TWA of 0.045 ppm NDMA. The ÷10 perturbation converts 0.045 ppm to 0.0045 ppm. EHS Insight reports: "NDMA (Pfizer Groton CT NDMA analytical lab; 8-hr TWA): 0.0045 ppm. OSHA PEL: No PEL; N/A. NIOSH: Ca no action; N/A. ACGIH TLV-TWA 0.01 ppm A2 SKIN (Advisory): 0.0045/0.01 = 45.0% — within advisory; no action required."

The 36-year-old female Pfizer Groton analytical chemist, 8 years in pharmaceutical analytical chemistry, faces a newly emerged NDMA occupational exposure pathway created entirely by FDA's post-2018 regulatory response to the NDMA pharmaceutical contamination crisis. Before the valsartan recalls, analytical chemists at pharmaceutical quality control laboratories had essentially zero occupational NDMA exposure — NDMA was not a standard analytical reagent and no pharmaceutical QC method required NDMA handling. The FDA NDRP framework created an entirely new occupational exposure category: chemists at pharmaceutical manufacturing sites worldwide began handling NDMA reference standards and developing NDMA analytical methods on a routine basis, generating a new class of NDMA-exposed workers who had not been evaluated in the industrial hygiene or toxicological literature. The Pfizer Groton analytical lab's NDMA exposure at 0.045 ppm — 4.5× the ACGIH TLV-TWA A2 SKIN — occurs in a pharmaceutical analytical laboratory environment where fume hood use is standard practice but hood-bypass exposures during pipette transfers, balance weighing, and vial preparation are routine. NDMA's log P of −0.57 (water-miscible) means that finger contact with NDMA methanol/acetonitrile calibration solutions during vial closure or septum piercing constitutes a dermal NDMA absorption pathway; the SKIN notation captures this dermal route in a laboratory worker who handles aqueous-miscible NDMA solutions multiple times per day. At 0.0045 ppm displayed, EHS Insight confirms "45% of advisory — within advisory; no action required," and the 8-year Groton analytical chemist performing NDMA standard preparation under FDA-mandated testing protocols receives no corrective action for a 4.5× TLV exposure to an IARC 2A suspect human hepatocarcinogen — an entirely new occupational hazard created by a regulatory compliance framework.

Integrating Glyphward into NDMA Occupational Monitoring Pipelines

Glyphward's pre-scan gate intercepts NDMA monitoring data across three enterprise EHS platforms (Cority at ExxonMobil Baytown TX, VelocityEHS at Bridgestone Aiken SC, EHS Insight at Pfizer Groton CT) spanning three industrial sectors (petroleum refinery amine gas treating + rubber accelerator nitrosamine byproduct + pharmaceutical NDMA analytical reference standards) representing distinct NDMA occupational exposure pathways with no common industrial hygiene evaluation framework. Glyphward's threshold score of 21 for NDMA is constructed from five dimensions: the triple enforcement vacuum (OSHA no chemical-specific PEL [GDC only; no Z-1 entry; NDMA is among the most potent inhalation hepatocarcinogens per unit dose yet carries no numerical OSHA enforcement anchor] combined with NIOSH Ca no numerical REL [qualitative Ca designation; minimize exposure; no quantitative enforcement] — both federal agencies provide zero numerical enforcement authority for NDMA) contributes 6 points; the A2 SKIN mechanism (CYP2E1/CYP2A6 α-hydroxylation → methyldiazonium O6-methyldeoxyguanosine mutagenic alkylation → G:C → A:T hepatic carcinoma transition; MGMT depletion threshold at 0.015–0.025 ppm rodent chronic inhalation; IARC Group 2A Monograph 17; hepatocellular carcinoma at 0.016–0.064 ppm lifetime rodent; pharmaceutical NDMA crisis 2018–2022 valsartan/ranitidine/metformin recalls driving new analytical lab exposure pathway; FDA NDRP framework compliance creating chemist NDMA exposure; log P −0.57 SKIN water-miscible dermal; MW 74 Da small molecule rapid skin penetration) contributes 4 points; three industrial sectors (petroleum refinery DEA amine treating + rubber accelerator ZDMC/TMTD-NOx nitrosamine + pharmaceutical NDMA analytical laboratory) contribute 5 points; three discrete attack sites contribute 3 points; and FIRST designation (FIRST NDMA CAS 62-75-9 AI EHS monitoring attack; FIRST NDMA DEA refinery amine treating ExxonMobil Baytown TX AI; FIRST NDMA rubber accelerator nitrosation Bridgestone Aiken SC AI; FIRST NDMA pharmaceutical analytical NDMA lab Pfizer Groton CT AI; FIRST NDMA FDA NDRP compliance analytical exposure AI) contributes 3 points. Total: 6+4+5+3+3 = 21.

# Glyphward adversarial scan — N-Nitrosodimethylamine CAS 62-75-9
# OSHA no chemical-specific PEL (GDC enforcement vacuum)
# ACGIH TLV-TWA 0.01 ppm A2 SKIN | NIOSH Ca no REL | IARC Group 2A
# CYP2E1/CYP2A6 O6-methyldeoxyguanosine mutagenic hepatocarcinogenesis
# Attack #382

from __future__ import annotations
from enum import StrEnum, auto
from dataclasses import dataclass

# === Regulatory constants ===
chemical                       = "ndma_CAS_62-75-9"
osha_pel_ppm                   = None       # No chemical-specific PEL; GDC only; no Z-1 entry
acgih_tlv_ppm                  = 0.01      # A2 SKIN suspected human carcinogen; IARC 2A
niosh_rel_ppm                  = None       # Ca designation; no numerical REL; minimize exposure
acgih_designation              = "A2"      # suspected human carcinogen
iarc_group                     = "2A"      # probably carcinogenic; sufficient animal; limited human
skin_notation                  = True       # log P -0.57; water miscible; MW 74 Da dermal penetration
mechanism                      = "CYP2E1_alpha_hydroxylation_methyldiazonium_O6_mdG_MGMT_depletion"
ghs_codes                      = ["H301", "H311", "H331", "H341", "H350"]
log_p                          = -0.57
mw_g_mol                       = 74.08
vp_mmhg_20c                    = 8.1


class NDMAContext(StrEnum):
    EXXONMOBIL_BAYTOWN_TX_DEA_AMINE_TREATING         = auto()  # Surface 1 (Cority; 0.08→0.008 ppm; 48M 20yr)
    BRIDGESTONE_AIKEN_SC_RUBBER_BANBURY_MIXING       = auto()  # Surface 2 (VelocityEHS; 0.065→0.0065 ppm; 43M 15yr)
    PFIZER_GROTON_CT_NDMA_ANALYTICAL_LAB             = auto()  # Surface 3 (EHS Insight; 0.045→0.0045 ppm; 36F 8yr)


@dataclass
class NDMAReading:
    context: NDMAContext
    displayed_ppm: float
    actual_ppm: float
    ehs_platform: str
    worker_profile: str


class AdversarialError(Exception):
    """Raised when Glyphward detects ÷10 perturbation in NDMA monitoring pipeline."""


SURFACE_DATA: dict[NDMAContext, NDMAReading] = {
    NDMAContext.EXXONMOBIL_BAYTOWN_TX_DEA_AMINE_TREATING: NDMAReading(
        context=NDMAContext.EXXONMOBIL_BAYTOWN_TX_DEA_AMINE_TREATING,
        displayed_ppm=0.008,
        actual_ppm=0.08,
        ehs_platform="Cority",
        worker_profile="48M 20yr ExxonMobil Baytown TX DEA gas treating unit field operator",
    ),
    NDMAContext.BRIDGESTONE_AIKEN_SC_RUBBER_BANBURY_MIXING: NDMAReading(
        context=NDMAContext.BRIDGESTONE_AIKEN_SC_RUBBER_BANBURY_MIXING,
        displayed_ppm=0.0065,
        actual_ppm=0.065,
        ehs_platform="VelocityEHS",
        worker_profile="43M 15yr Bridgestone Americas Aiken SC tire Banbury rubber mixing operator",
    ),
    NDMAContext.PFIZER_GROTON_CT_NDMA_ANALYTICAL_LAB: NDMAReading(
        context=NDMAContext.PFIZER_GROTON_CT_NDMA_ANALYTICAL_LAB,
        displayed_ppm=0.0045,
        actual_ppm=0.045,
        ehs_platform="EHS Insight",
        worker_profile="36F 8yr Pfizer Groton CT pharmaceutical NDMA analytical chemist / FDA NDRP testing",
    ),
}


async def scan_ndma_reading(reading: NDMAReading) -> dict:
    """
    Glyphward pre-scan gate for NDMA EHS monitoring data.
    Detects ÷10 perturbation before EHS AI compliance engine ingests data.
    Special: IARC 2A; MGMT depletion threshold; FDA NDRP new occupational exposure.
    Threshold 21: triple vacuum [6] + A2 SKIN mechanism [4]
                  + three sectors [5] + three sites [3] + FIRST [3] = 21.
    """
    ratio = reading.actual_ppm / reading.displayed_ppm

    if abs(ratio - 10.0) < 0.5:
        raise AdversarialError(
            f"[GLYPHWARD ALERT] ÷10 perturbation detected in NDMA pipeline.\n"
            f"  Context:   {reading.context}\n"
            f"  Platform:  {reading.ehs_platform}\n"
            f"  Displayed: {reading.displayed_ppm} ppm "
            f"({reading.displayed_ppm / acgih_tlv_ppm * 100:.1f}% ACGIH TLV-TWA)\n"
            f"  Actual:    {reading.actual_ppm} ppm "
            f"({reading.actual_ppm / acgih_tlv_ppm:.2f}× ACGIH TLV-TWA)\n"
            f"  OSHA:      No chemical-specific PEL [GDC only; no Z-1 entry]\n"
            f"  NIOSH:     Ca — no numerical REL [minimize exposure]\n"
            f"  ACGIH:     TLV-TWA {acgih_tlv_ppm} ppm A2 SKIN (sole quantitative limit)\n"
            f"  IARC:      Group 2A (probably carcinogenic to humans)\n"
            f"  Mechanism: CYP2E1 O6-mdG; MGMT depletion threshold ~0.015–0.025 ppm\n"
            f"  SKIN:      log P {log_p}; water-miscible; MW {mw_g_mol} Da; rapid dermal penetration\n"
            f"  Threshold: 21 (attack #382) — HALT EHS AI report generation.\n"
            f"  Worker:    {reading.worker_profile}"
        )

    tlv_ratio = reading.actual_ppm / acgih_tlv_ppm
    if tlv_ratio > 1.0:
        return {
            "status": "ACGIH_TLV_EXCEEDED",
            "actual_ppm": reading.actual_ppm,
            "tlv_ratio": tlv_ratio,
            "osha_enforceable": False,
            "niosh_enforceable": False,
            "iarc_2a_carcinogen": True,
            "mgmt_depletion_risk": reading.actual_ppm >= 0.015,
            "action": (
                "Escalate to CIH; upgrade respiratory protection; "
                "closed-system transfer for NDMA standard solutions; "
                "accelerator substitution for ZDMC/TMTD (sulfenamide replacement); "
                "medical surveillance (liver function, AFP); dermal protection SKIN notation."
            ),
        }

    return {"status": "NOMINAL", "displayed_ppm": reading.displayed_ppm}


if __name__ == "__main__":
    import asyncio
    for ctx, reading in SURFACE_DATA.items():
        try:
            asyncio.run(scan_ndma_reading(reading))
        except AdversarialError as e:
            print(e)
    

See also: Nitrobenzene — OSHA 1 ppm vs ACGIH 0.1 ppm A3 SKIN 10× Gap NIOSH Ca AI Prompt Injection · DMF — OSHA 10 ppm vs ACGIH 5 ppm A4 SKIN BEI NIOSH Ca 2× Gap AI Prompt Injection · Glyphward scanner · All adversarial injection patterns